Motif Bio Share Discussion Threads

[rizler] 18/8/2017 08:11

Wonder what is causing this to drift?

[someuwin] 15/8/2017 15:55

Been picking up a few more of these.

[slider27] 14/8/2017 15:19

Can anybody help me out as i am trying to understand the ISIN number of the warrants traded on the nasdaq as thinking of buying a few
Much appreciated if anybody has any info or can point me in the right direction

[dstorey1] 11/8/2017 17:52

What are the chances that this will be an independent concern going into 2018?

[razmo1] 10/8/2017 09:07

I absolutely take your point ilovetowin but if he key milestones continue to come in, on time and positive then at some point this has to move.

I'm at a loss why it's so undervalued compared to peers but so far it's delivering in terms of the product and science.

[blueblood] 10/8/2017 09:02

Need to chill out and come back at end of September as this isn't going anywhere in meantime by looks of it.

[ilovetowin] 10/8/2017 08:48

Key milstone. Hmmm.Didn't we have a "key milstone" in April?Positive data readout? And a US25 million dollar raise at 30pOh and let's not forget giving Mr Bertoldi a front hander of 125,000 dollars to keep AMP from dumping and destroying the share price Yes LPO was indeed a key milstone.We've had many if those.29p bid.

[blueblood] 10/8/2017 08:34

It's Revive2 readout we are waiting for and LPO is key milestone and means countdown is on with results expected in around 6-8 weeks from now.

[ilovetowin] 10/8/2017 08:16

LPO everyone was waiting for. Speculation on the dates. The tension. The hope. The result: Nada. 29 bid.

[dstorey1] 09/8/2017 11:14

Back in with speculative buy, even after previous misgivings regards US IPO. GLA.

[waterloo01] 09/8/2017 10:38

Few on here following? Happy to buy back in at 29p. Be interesting to see how Nasdaq responds.

[ilovetowin] 04/8/2017 21:18

Seems more than happy trading well below the big placing priceNo idea why it's trading like this after such huge news effectively derisking the company Big shame.

[drmaccers] 04/8/2017 19:30

Still in Banshee but awaiting revive 2 to do the talking!I've been adding

[ny boy] 27/7/2017 15:20

Just buy these pull backs Sir!

[philoosh] 25/7/2017 16:32

It seems to be slowly slipping down further and further.

[nick rubens] 20/7/2017 15:15

Won't final results and potential FDA approval for Iclaprim be known in the first half of 2018? Maybe closer to then the share price will react more strongly?

[ilovetowin] 20/7/2017 12:59

Big disappointment here

[banshee] 19/7/2017 20:17

"If you want a small antibiotic company whose products have some real prospect, I'd look at Tetraphase in the US"

That sounds suspiciously like a tip to me Vulgaris. See you on LSE hopefully. Ivyspivey and Dr Maccers, who seems to be on sabbatical, and used to post on here occasionally, are the relevant professionals there.

[vulgaris] 19/7/2017 19:57

I don't think I tipped them, but what I would say is that Tetraphase have some very interesting chemistry for modifying tetracyclines. They can synthesise large numbers of different molecules whereas, previously, this was difficult and slow.

Their mistake, with their lead molecule, eravacycline, was an iv/oral switch trial in UTI. Patients who switched early tended to fail, the implication being that that oral wasn't giving adequate levels.... They're now doing another cUTI trial with iv only.

I'll look at the LSE board.

[banshee] 19/7/2017 16:44

Ah Vulgaris, I wondered where you had got to. All the action on this one is on the LSE BB, where you could debate with other industry professionals, it is pretty much a graveyard here.

Meanwhile, didn't you tip Tetraphase just before it crashed 90% or so? Or was that someone else?

[vulgaris] 19/7/2017 16:30

Banshee: apropos delafloxacin. Its merit is scope for iv to oral switch. As you note it's a fluoroquinolone; several fluoroquinolones have come unstuck post-licensing owing to rare toxicities but others (cipro- and levo-) have been highly successful. Only time will tell...

HABP trials for any antibiotic are more costly than ABSSSI as harder to recruit patients..... fewer cases and more excluded owing to having already received other agents.

[banshee] 18/7/2017 13:22

REVIVE-2 has finished recruiting, so Last Patient Out should be RNS announced in a week or so. The Pacyhderm in the Pantry however, remains the potential requirement for further funding re INSPIRE.